Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JSCPT Symposium Focuses on Adaptive Design
January 5, 2009
- % of Patients on Drugs for Hypertension Lowest in Japan: 15-Country Survey
January 5, 2009
- Japan Needs Basic Systems for Global Clinical Trials: Prof. Ohashi
January 5, 2009
- Promotion of Use of Generics Essential to Have Industry-Proposed Pricing System Introduced
January 5, 2009
- Conduct Clinical Development Based on Assumption That There Are Ethnic Differences
January 5, 2009
- Korosho Asks Insurers to Participate in Councils for Promotion of the Use of Generics
January 5, 2009
- R&D NEWS IN BRIEF
January 5, 2009
- Korosho to Provide ¥20 Bil. by Promoting Use of Generics
January 5, 2009
- JPhA to Demand Direct Talk with Korosho
January 5, 2009
- JHIA to Promote Use of Generics
January 5, 2009
- Etizolam, Loxoprofen Taken during Pregnancy Don't Increase Incidence of Malformations
January 5, 2009
- Global Sales of Generics Totaled US$78.0 Bil. in 2007
January 5, 2009
- Ciclosporin Is Useful Option for Patients Resistant to Steroids: Dr Igarashi
January 5, 2009
- Dissolution of Original and Generic UDCA Products to Be Studied by NIHS
January 5, 2009
- Infliximab Can Be Withdrawn for Over 1 Year in Majority of Patients: Prof. Tanaka
January 5, 2009
- Prasugrel Receives Positive Opinion from CHMP
January 5, 2009
- Tokai Univ. Holds Seminars on Cancer Therapy for General Clinicians
January 5, 2009
- FDA Approves Eisai's Sedative-Hypnotic Agent LUSEDRA Injection
January 5, 2009
- Pirespa Inhibits Progression of Mild to Moderate IPF
January 5, 2009
- PMDA to Enforce New Conflict of Interest Regulations in January
January 5, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…